WILMINGTON, DE — InSilicoTrials has been accepted into the prestigious Microsoft for Startups Pegasus Program, an exclusive initiative designed to accelerate the growth of high-potential startups in sectors including AI, healthcare, and cybersecurity. This significant milestone underscores a shared commitment to revolutionizing healthcare research and development through cutting-edge technologies.
The Pegasus Program offers growth-stage startups access to Microsoft’s expansive global sales channels, enterprise customer network, and advanced cloud infrastructure. For InSilicoTrials, this collaboration opens the door to leveraging Microsoft Azure’s capabilities to advance its suite of AI-driven and in silico simulation tools aimed at streamlining pharmaceutical and biotech R&D.
“InSilicoTrials is focused on expanding access to simulation and AI tools that help life sciences organizations de-risk faster development of safer, more effective treatments,” said Luca Emili, CEO of InSilicoTrials. “Joining the Microsoft for Startups Pegasus Program allows us to scale our reach, enhance our integration with Microsoft Azure, and bring the benefits of in silico trials to more customers worldwide.”
InSilicoTrials’ platform is designed to support pharmaceutical companies and researchers in optimizing clinical trials, reducing reliance on traditional methods, and speeding up the development of new therapies. Key innovations include digital twin and virtual patient technologies, AI-driven simulations, and synthetic patient populations, all targeted at making drug development faster, safer, and more efficient.
Participation in the program will also enable the company’s solutions to be available via the Azure Marketplace, simplifying access for enterprise customers. With co-sell opportunities and joint go-to-market efforts alongside Microsoft’s sales and technical teams, the partnership adds significant scalability to the company’s mission.
“We are pleased to welcome InSilicoTrials into the Microsoft for Startups Pegasus Program,” said Sally Ann Frank, Global Lead for Health & Life Sciences at Microsoft for Startups. “We look forward to supporting their efforts to bring advanced digital simulation and AI technologies to life sciences organizations, transforming healthcare and accelerating innovation in drug development.”
This partnership aims to propel the broader healthcare and life sciences industries toward a future where R&D processes are not only optimized but also more inclusive and efficient. Through its integration with Microsoft’s infrastructure, InSilicoTrials is poised to reshape the way treatments are developed and delivered worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.